YI Quote, Financials, Valuation and Earnings

Dr. Reddy's Laboratories Ltd. has a net margin of -0.5% compared to 111, Inc.'s net margin of 13.63%. 111, Inc.'s return on equity of -26.11% beat Dr. Reddy's Laboratories Ltd.'s return on equity of 15.8%.

111, Inc. has a consensus price target of --, signalling upside risk potential of 832.32%. On the other hand Dr. Reddy's Laboratories Ltd. has an analysts' consensus of $14.32 which suggests that it could grow by 7.57%. Given that 111, Inc. has higher upside potential than Dr. Reddy's Laboratories Ltd., analysts believe 111, Inc. is more attractive than Dr. Reddy's Laboratories Ltd..

111, Inc. has a beta of 0.691, which suggesting that the stock is 30.919% less volatile than S&P 500. In comparison Dr. Reddy's Laboratories Ltd. has a beta of 0.346, suggesting its less volatile than the S&P 500 by 65.416%.

111, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dr. Reddy's Laboratories Ltd. offers a yield of 0.71% to investors and pays a quarterly dividend of $0.09 per share. 111, Inc. pays -- of its earnings as a dividend. Dr. Reddy's Laboratories Ltd. pays out 8.91% of its earnings as a dividend. Dr. Reddy's Laboratories Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

111, Inc. quarterly revenues are $419.3M, which are smaller than Dr. Reddy's Laboratories Ltd. quarterly revenues of $979.5M. 111, Inc.'s net income of -$2.1M is lower than Dr. Reddy's Laboratories Ltd.'s net income of $133.5M. Notably, 111, Inc.'s price-to-earnings ratio is -- while Dr. Reddy's Laboratories Ltd.'s PE ratio is 16.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 111, Inc. is 0.03x versus 2.77x for Dr. Reddy's Laboratories Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Sinovac Biotech Ltd. has a net margin of -0.5% compared to 111, Inc.'s net margin of --. 111, Inc.'s return on equity of -26.11% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.

111, Inc. has a consensus price target of --, signalling upside risk potential of 832.32%. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that 111, Inc. has higher upside potential than Sinovac Biotech Ltd., analysts believe 111, Inc. is more attractive than Sinovac Biotech Ltd..

111, Inc. has a beta of 0.691, which suggesting that the stock is 30.919% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.887, suggesting its less volatile than the S&P 500 by 11.313%.

111, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. 111, Inc. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.

111, Inc. quarterly revenues are $419.3M, which are larger than Sinovac Biotech Ltd. quarterly revenues of --. 111, Inc.'s net income of -$2.1M is higher than Sinovac Biotech Ltd.'s net income of --. Notably, 111, Inc.'s price-to-earnings ratio is -- while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 111, Inc. is 0.03x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Zai Lab Ltd. has a net margin of -0.5% compared to 111, Inc.'s net margin of -39.51%. 111, Inc.'s return on equity of -26.11% beat Zai Lab Ltd.'s return on equity of -22.45%.

111, Inc. has a consensus price target of --, signalling upside risk potential of 832.32%. On the other hand Zai Lab Ltd. has an analysts' consensus of $38.47 which suggests that it could grow by 88.47%. Given that 111, Inc. has higher upside potential than Zai Lab Ltd., analysts believe 111, Inc. is more attractive than Zai Lab Ltd..

111, Inc. has a beta of 0.691, which suggesting that the stock is 30.919% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.859, suggesting its less volatile than the S&P 500 by 14.084%.

111, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 111, Inc. pays -- of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.

111, Inc. quarterly revenues are $419.3M, which are larger than Zai Lab Ltd. quarterly revenues of $128.2M. 111, Inc.'s net income of -$2.1M is higher than Zai Lab Ltd.'s net income of -$50.6M. Notably, 111, Inc.'s price-to-earnings ratio is -- while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 111, Inc. is 0.03x versus 4.87x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.